Literature DB >> 11003454

Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations.

M Vogelbruch1, B Nuss, M Körner, A Kapp, P Kiehl, W Bohm.   

Abstract

BACKGROUND: The development of persistent subcutaneous nodules at the injection sites of aluminium-adsorbed hyposensitization solutions is rare. These nodules have been interpreted as a delayed, granulomatous hypersensitivity reaction to aluminium. We report for the first time a case of persistent intradermal granulomas that developed at the sites of inaccurate intradermal, instead of subcutaneous, hyposensitization injections.
METHODS: An intradermal nodule was excised and processed for histopathology, scanning electron microscopy, and X-ray microanalysis. Intradermal and patch tests with aluminium hydroxide were performed.
RESULTS: Histologically, the nodule presented a pattern of granulomatous inflammatory reaction surrounding foci of necrotic tissue. Scanning electron microscopy and X-ray microanalysis revealed deposits of aluminium within the granulomas. Patch tests with aluminium hydroxide were negative, and intradermal tests caused persistent intradermal granulomas. Subsequent hyposensitization therapy in our department with the usual subcutaneous injections of aluminium-adsorbed allergen extracts was well tolerated by the patient.
CONCLUSIONS: Local toxic effects of aluminium may be crucial in the development of persistent intradermal injection-site granulomas. Such intradermal nodules may develop even if the subcutaneous route is well tolerated. We conclude that inaccurate intradermal injections of aluminium-containing solutions have to be strictly avoided.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11003454

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  23 in total

1.  Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy.

Authors:  Hans Grönlund; Susanne Vrtala; Ursula Wiedermann; Gerhard Dekan; Dietrich Kraft; Rudolf Valenta; Marianne Van Hage-Hamsten
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Microneedles with intrinsic immunoadjuvant properties: microfabrication, protein stability, and modulated release.

Authors:  Alexander K Andrianov; Alexander Marin; Daniel P DeCollibus
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 3.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

Review 4.  Key roles of adjuvants in modern vaccines.

Authors:  Steven G Reed; Mark T Orr; Christopher B Fox
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

5.  Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization.

Authors:  Alexander K Andrianov; Daniel P DeCollibus; Helice A Gillis; Henry H Kha; Alexander Marin; Mark R Prausnitz; Lorne A Babiuk; Hugh Townsend; George Mutwiri
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-28       Impact factor: 11.205

6.  Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.

Authors:  Mariana Baz; Mukesh Samant; Hakima Zekki; Pascale Tribout-Jover; Martin Plante; Anne-Marie Lanteigne; Marie-Eve Hamelin; Corey Mallett; Barbara Papadopoulou; Guy Boivin
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

Review 7.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

8.  Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization.

Authors:  Yuh-Fun Maa; Cassandra Shu; Mahmoud Ameri; Cindy Zuleger; Jenny Che; Jorge E Osorio; Lendon G Payne; Dexiang Chen
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

9.  A novel adjuvant-allergen complex, CBP-rFel d 1, induces up-regulation of CD86 expression and enhances cytokine release by human dendritic cells in vitro.

Authors:  Theresa N Andersson; Gunilla J Ekman; Hans Grönlund; Eva Buentke; Tove L J Eriksson; Annika Scheynius; Marianne Van Hage-Hamsten; Guro Gafvelin
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

10.  Natural STING Agonist as an "Ideal" Adjuvant for Cutaneous Vaccination.

Authors:  Ji Wang; Peiyu Li; Mei X Wu
Journal:  J Invest Dermatol       Date:  2016-06-07       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.